EAM Investors LLC Acquires Shares of 109,555 Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)

EAM Investors LLC purchased a new stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 109,555 shares of the company's stock, valued at approximately $451,000. EAM Investors LLC owned about 0.18% of Eledon Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Inspire Investing LLC acquired a new stake in shares of Eledon Pharmaceuticals in the 4th quarter valued at approximately $802,000. Charles Schwab Investment Management Inc. grew its position in shares of Eledon Pharmaceuticals by 100.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 29,987 shares of the company's stock valued at $124,000 after acquiring an additional 15,000 shares during the period. Geode Capital Management LLC grew its position in shares of Eledon Pharmaceuticals by 9.7% in the 3rd quarter. Geode Capital Management LLC now owns 378,058 shares of the company's stock valued at $942,000 after acquiring an additional 33,569 shares during the period. Virtu Financial LLC acquired a new position in shares of Eledon Pharmaceuticals during the 4th quarter worth about $82,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Eledon Pharmaceuticals in the 4th quarter valued at about $66,000. 56.77% of the stock is currently owned by institutional investors.

Eledon Pharmaceuticals Price Performance

Eledon Pharmaceuticals stock traded up $0.05 during mid-day trading on Wednesday, hitting $3.43. 84,064 shares of the company's stock traded hands, compared to its average volume of 284,875. The firm has a 50 day simple moving average of $3.55 and a two-hundred day simple moving average of $3.95. Eledon Pharmaceuticals, Inc. has a fifty-two week low of $1.91 and a fifty-two week high of $5.54. The stock has a market cap of $205.40 million, a price-to-earnings ratio of -1.71 and a beta of 0.66.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.32). During the same period in the prior year, the business posted ($1.00) EPS. On average, research analysts anticipate that Eledon Pharmaceuticals, Inc. will post -0.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Guggenheim began coverage on Eledon Pharmaceuticals in a report on Tuesday, January 28th. They set a "buy" rating and a $9.00 price target for the company.

Eledon Pharmaceuticals Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).